{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:55:14Z","timestamp":1777384514322,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.ejso.2021.01.013","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T06:22:45Z","timestamp":1611296565000},"page":"1427-1433","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Pattern of recurrence after interval cytoreductive surgery and HIPEC following neoadjuvant chemotherapy in primary advanced stage IIIC\/IVA epithelial ovarian cancer"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5719-2873","authenticated-orcid":false,"given":"Snita","family":"Sinukumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0367-994X","authenticated-orcid":false,"given":"Dileep","family":"Damodaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7059-5383","authenticated-orcid":false,"given":"Mukurdipi","family":"Ray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0035-5499","authenticated-orcid":false,"given":"Sanket","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5169-3578","authenticated-orcid":false,"given":"Lista","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9808-6898","authenticated-orcid":false,"given":"Aditi","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejso.2021.01.013_bib1","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.ygyno.2006.06.028","article-title":"The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer","volume":"103","author":"Eisenhauer","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2021.01.013_bib2","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.ygyno.2006.06.025","article-title":"Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis","volume":"103","author":"Bristow","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2021.01.013_bib3","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J\u00a0Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"14","key":"10.1016\/j.ejso.2021.01.013_bib4","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.ejca.2006.03.025","article-title":"Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: clinical considerations","volume":"42","author":"Ferrandina","year":"2006","journal-title":"Eur J Cancer Oxf Engl"},{"issue":"9","key":"10.1016\/j.ejso.2021.01.013_bib5","doi-asserted-by":"crossref","DOI":"10.1097\/IGC.0000000000000007","article-title":"Ovarian cancer: sites of recurrence","volume":"23","author":"Amate","year":"2013","journal-title":"Int J Gynecol Canc"},{"issue":"1","key":"10.1016\/j.ejso.2021.01.013_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40944-017-0148-7","article-title":"Cytoreductive surgery and HIPEC in the first-line and interval time points of advanced epithelial ovarian cancer","volume":"15","author":"Kusamura","year":"2017","journal-title":"Indian J Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2021.01.013_bib7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"25","key":"10.1016\/j.ejso.2021.01.013_bib8","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.2174\/138161212802002616","article-title":"Survival benefit of adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidence","volume":"18","author":"Mulier","year":"2012","journal-title":"Curr Pharmaceut Des"},{"issue":"4","key":"10.1016\/j.ejso.2021.01.013_bib9","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1245\/s10434-016-5686-1","article-title":"Cytoreduction (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced ovarian cancer: retrospective Italian multicenter observational study of 511 cases","volume":"24","author":"Di Giorgio","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2021.01.013_bib10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ygyno.2011.09.011","article-title":"Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer","volume":"124","author":"Tanner","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2021.01.013_bib11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ygyno.2012.05.026","article-title":"Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy","volume":"127","author":"Esselen","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2021.01.013_bib12","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.ejso.2021.01.013_bib13","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","article-title":"Peritonectomy procedures","volume":"221","author":"Sugarbaker","year":"1995","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.ejso.2021.01.013_bib14","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s13193-016-0505-5","article-title":"Cytoreductive surgery and peritonectomy procedures","volume":"7","author":"Mehta","year":"2016","journal-title":"Indian J Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2021.01.013_bib16","article-title":"Effect of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on relapse pattern in primary epithelial ovarian cancer: a propensity score based case-control study","volume":"29","author":"Ceresoli","year":"2018","journal-title":"J\u00a0Gynecol Oncol"},{"key":"10.1016\/j.ejso.2021.01.013_bib17","first-page":"24","article-title":"Recurrence patterns of advanced ovarian, fallopian tube, and peritoneal cancers after complete cytoreduction during interval debulking surgery","author":"Usami","year":"2014","journal-title":"Int J Gynecol Canc"},{"issue":"12","key":"10.1016\/j.ejso.2021.01.013_bib18","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1245\/s10434-013-3091-6","article-title":"Timing and pattern of recurrence in ovarian cancer patients with high tumor dissemination treated with primary debulking surgery versus neoadjuvant chemotherapy","volume":"20","author":"Petrillo","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10.1016\/j.ejso.2021.01.013_bib19","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1245\/s10434-012-2400-9","article-title":"Systematic pelvic and aortic lymphadenectomy in advanced ovarian cancer patients at the time of interval debulking surgery: a double-institution case\u2013control study","volume":"19","author":"Fagotti","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2021.01.013_bib20","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1006\/gyno.1996.0249","article-title":"Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: prognostic significance of node metastases","volume":"62","author":"Re","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejso.2021.01.013_bib21","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.bulcan.2019.01.014","article-title":"Management of epithelial ovarian cancer. Short text drafted from the French joint recommendations of FRANCOGYN, CNGOF, SFOG, GINECO\u2013ARCAGY and endorsed by INCa","volume":"106","author":"Lavoue","year":"2019","journal-title":"Bull Cancer"},{"issue":"2","key":"10.1016\/j.ejso.2021.01.013_bib22","first-page":"169","article-title":"Are nodal metastases in ovarian cancer chemoresistant lesions? Analysis of nodal involvement in 105 patients treated with preoperative chemotherapy","volume":"25","author":"Morice","year":"2004","journal-title":"Eur J Gynaecol Oncol"},{"issue":"8","key":"10.1016\/j.ejso.2021.01.013_bib23","first-page":"2427","article-title":"Impact of lymphadenectomy on survival of patients with serous advanced ovarian cancer after neoadjuvant chemotherapy: a French national multicenter study (FRANCOGYN)","volume":"9","author":"Bund","year":"2020","journal-title":"J\u00a0Clin Med"},{"issue":"4","key":"10.1016\/j.ejso.2021.01.013_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2018-000200","article-title":"Therapeutic value of selective lymphadenectomy in interval debulking surgery for stage IIIc and IV epithelial ovarian cancer","volume":"29","author":"Song","year":"2019","journal-title":"Int J Gynecol Canc"},{"issue":"12","key":"10.1016\/j.ejso.2021.01.013_bib25","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1016\/j.ejso.2019.07.019","article-title":"Pathological assessment of cytoreductive surgery specimens and its unexplored prognostic potential-a prospective multi-centric study","volume":"45","author":"Bhatt","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2021.01.013_bib26","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ygyno.2012.11.007","article-title":"Is perioperative visual estimation of intraabdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy?","volume":"128","author":"Hynninen","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2021.01.013_bib27","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00276-008-0456-9","article-title":"Peritoneal surface area: measurements of 40 structures covered by peritoneum: correlation between total peritoneal surface area and the surface calculated by formulas","volume":"31","author":"Albanese","year":"2009","journal-title":"Surg Radiol Anat"},{"key":"10.1016\/j.ejso.2021.01.013_bib28","series-title":"Advances in peritoneal surface oncology","first-page":"11","article-title":"The natural history of free cancer cells in the peritoneal cavity","author":"Yonemura","year":"2007"},{"issue":"19","key":"10.1016\/j.ejso.2021.01.013_bib29","first-page":"30304","article-title":"A\u00a0comparison of outcomes following total and selective peritonectomy performed at the time of interval cytoreductive surgery for advanced serous epithelial ovarian, fallopian tube and primary peritoneal cancer \u2013 a study by INDEPSO","volume":"7983","author":"Sinukumar","year":"2019","journal-title":"Eur J Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2021.01.013_bib30","first-page":"324","article-title":"Residual cancer stem cells after interval cytoreductive surgery following neoadjuvant chemotherapy could result in poor treatment outcomes for ovarian cancer","volume":"33","author":"Lim","year":"2010","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.ejso.2021.01.013_bib31","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1245\/s10434-012-2237-2","article-title":"Cytoreductive surgery with selective versus complete parietal peritonectomy followed by hyperthermic intraperitoneal chemotherapy in patients with diffuse malignant peritoneal mesothelioma: a controlled study","volume":"19","author":"Baratti","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10.1016\/j.ejso.2021.01.013_bib32","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/j.ejso.2019.06.021","volume":"45","author":"Deraco","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2021.01.013_bib33","article-title":"Total parietal peritonectomy can Be performed with acceptable morbidity for patients with advanced ovarian cancer after neoadjuvant chemotherapy: results from a prospective multi-centric study","author":"Bhatt","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2021.01.013_bib34","first-page":"1","article-title":"ASO author reflections: total parietal peritonectomy during interval cytoreductive surgery for advanced ovarian cancer\u2014proof-of-principle and analysis of morbidity","author":"Bhatt","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2021.01.013_bib35","series-title":"Molecular mechanisms of platinum resistance in ovarian cancer","author":"Tapia","year":"2013"},{"issue":"27","key":"10.1016\/j.ejso.2021.01.013_bib36","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1200\/JCO.19.00194","article-title":"Management of platinum-resistant, relapsed epithelial ovarian cancer and new drug perspectives","volume":"37","author":"Pujade-Lauraine","year":"2019","journal-title":"J\u00a0Clin Oncol"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798321000408?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798321000408?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:37:02Z","timestamp":1760060222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798321000408"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0748798321000408"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2021.01.013","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pattern of recurrence after interval cytoreductive surgery and HIPEC following neoadjuvant chemotherapy in primary advanced stage IIIC\/IVA epithelial ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2021.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.","name":"copyright","label":"Copyright"}]}}